Company intelligence / Profile preview

Winteam Pharmaceutical Group

Hong Kong

Ownership: Private
Development stage: Other

Overview

Winteam operated as an investment holding company focused on pharmaceutical products and partnerships. The company had no active clinical development programs of its own but held exclusive commercial rights to several partnered products in greater China, including Hepa-Merz (L-ornithine L-aspartate) for liver disease and AC-203 for rare skin conditions.

Therapeutic areas: DermatologyNeurologyRare DiseasesGastroenterology
Modalities: Small moleculeRecombinant protein
Industry: Biotech

Partnerships

Sinopharm GroupQuoin PharmaceuticalsMerz PharmaTWi Biotechnology

Beyond the preview

Go deeper on Winteam Pharmaceutical Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Winteam Pharmaceutical Group.

Explore the full profile